ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
22.46
+0.04 (0.18%)
At close: Feb 13, 2026, 4:00 PM EST
22.75
+0.29 (1.29%)
After-hours: Feb 13, 2026, 6:32 PM EST
ArriVent BioPharma Market Cap
ArriVent BioPharma has a market cap or net worth of $927.18 million as of February 13, 2026. Its market cap has decreased by -5.41% in one year.
Market Cap
927.18M
Enterprise Value
626.97M
1-Year Change
-5.41%
Ranking
Category
Stock Price
$22.46
Market Cap Chart
Since the IPO on January 26, 2024, ArriVent BioPharma's market cap has increased from $575.22M to $927.18M, an increase of 61.19%. That is a compound annual growth rate of 26.19%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 13, 2026 | 927.18M | 11.63% |
| Dec 31, 2025 | 830.58M | -7.48% |
| Dec 31, 2024 | 897.69M | 56.06% |
| Jan 26, 2024 | 575.22M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Palvella Therapeutics | 970.83M |
| Fortrea Holdings | 948.95M |
| UroGen Pharma | 946.01M |
| Phathom Pharmaceuticals | 941.10M |
| Aktis Oncology | 940.15M |
| GH Research | 931.06M |
| CytomX Therapeutics | 920.03M |
| BridgeBio Oncology Therapeutics | 913.47M |